← All organizations
Highest phase reached
Phase 4
First clinical trial
Dec 1, 2001Last known activity
Jul 1, 2025
Defunct as of Dec 31, 2025
Timeline
1990s
- Jan 1, 1994
MediGene— Founded
2010s
- Jan 1, 2014
Trianta Immunotherapies— Acquired
2020s
- Dec 31, 2025
MediGene— Defunct
Drugs by trial phase (10 distinct, 17 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 2 (6 own, 0 via acquisition)
Phase 1 (3 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Astrocytoma
- Basal Cell Carcinoma
- Breast Neoplasms
- Carcinoma
- Colorectal Neoplasms
- Condylomata Acuminata
- Glioblastoma
- Glioma
- Hematologic Neoplasms
- Leukemia
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Liver Neoplasms
- Lymphoma
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Second Primary
- Pancreatic Neoplasms
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Signs and Symptoms
- Warts
Marketed drugs (1)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (20)
- NCT06748872Lead sponsorPhase 1Jul 1, 2025
- NCT04464889Study directorPhase 1Jul 2, 2020
- NCT04464889Lead sponsorPhase 1Jul 2, 2020
- NCT03503968Lead sponsorPhase 1/Phase 2Mar 27, 2018
- NCT02405338Lead sponsorPhase 1/Phase 2Mar 1, 2015
- NCT02029352CollaboratorPhase 2/Phase 3Nov 1, 2014
- NCT01490008Lead sponsorPhase 1Dec 1, 2011
- NCT01500122Lead sponsorPhase 1Dec 1, 2011
- NCT01082302Lead sponsorPhase 4Jan 1, 2010
- NCT00704119Lead sponsorPhase 1May 1, 2008
- NCT00542048Lead sponsorPhase 2Nov 1, 2007
- NCT00532012Lead sponsorPhase 1Sep 1, 2007
- NCT00448305Lead sponsorPhase 2Jan 1, 2007
- NCT00377936Lead sponsorPhase 2Sep 1, 2005
- NCT00157703Study directorPhase 1May 1, 2005
Details
- Founded
- Martinsried, DE Jan 1, 1994
- Last known activity
- Jul 1, 2025